Manning & Napier Group LLC Decreases Position in Qiagen NV (QGEN)
Manning & Napier Group LLC reduced its stake in Qiagen NV (NYSE:QGEN) by 13.7% in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 856,928 shares of the company’s stock after selling 135,808 shares during the period. Manning & Napier Group LLC owned 0.38% of Qiagen worth $34,858,000 at the end of the most recent reporting period.
Several other hedge funds and other institutional investors have also made changes to their positions in the business. Lindbrook Capital LLC purchased a new position in shares of Qiagen in the 4th quarter worth $25,000. Captrust Financial Advisors boosted its position in Qiagen by 165.3% in the 4th quarter. Captrust Financial Advisors now owns 1,008 shares of the company’s stock valued at $35,000 after buying an additional 628 shares during the period. Bremer Trust National Association purchased a new stake in Qiagen in the 4th quarter valued at about $45,000. Fort L.P. purchased a new stake in Qiagen in the 4th quarter valued at about $68,000. Finally, Oppenheimer Asset Management Inc. purchased a new stake in Qiagen in the 4th quarter valued at about $118,000. 64.77% of the stock is owned by institutional investors and hedge funds.
QGEN has been the subject of several recent research reports. Deutsche Bank restated a “buy” rating on shares of Qiagen in a report on Tuesday, January 29th. Jefferies Financial Group restated a “neutral” rating on shares of Qiagen in a report on Monday, January 21st. UBS Group initiated coverage on shares of Qiagen in a report on Friday, March 15th. They issued a “neutral” rating and a $42.00 price target for the company. Finally, Zacks Investment Research lowered shares of Qiagen from a “hold” rating to a “sell” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and six have issued a buy rating to the company. Qiagen currently has an average rating of “Hold” and an average target price of $41.17.
Qiagen (NYSE:QGEN) last announced its quarterly earnings results on Monday, February 4th. The company reported $0.40 earnings per share (EPS) for the quarter, hitting the Zacks’ consensus estimate of $0.40. The firm had revenue of $403.20 million for the quarter, compared to the consensus estimate of $409.32 million. Qiagen had a net margin of 12.68% and a return on equity of 12.15%. The firm’s quarterly revenue was up 1.6% compared to the same quarter last year. During the same period in the prior year, the firm posted $0.43 earnings per share. As a group, sell-side analysts forecast that Qiagen NV will post 1.45 earnings per share for the current year.
QIAGEN N.V. provides sample to insight solutions that transform biological materials into molecular insights worldwide. The company offers sample technologies for plasmid deoxyribonucleic acid (DNA) purification, ribonucleic acid purification and stabilization, genomic and viral nucleic acid purification, DNA cleanup after polymerase chain reaction (PCR) and sequencing, target enrichment, and library preparation for sequencing applications; and assay technology solutions.
Receive News & Ratings for Qiagen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Qiagen and related companies with MarketBeat.com's FREE daily email newsletter.